The approval to distribute products in China to significantly boost revenue growth in the coming quarters. See why I assign a hold rating to SWAV stock.
The global percutaneous aortic valve implantation market is expected to see striking growth by 2028, due to the increasing incidences of cardiovascular disorders among people globally. The North
/PRNewswire/ Cordis, a global leader in cardiovascular technologies, today announced that Bryan Loo will assume the role of President of the Asia-Pacific.
Shockwave Medical (SWAV) and Genesis MedTech said China's National Medical Products Administration ((NMPA)) approved the sale of Shockwave IVL System with the Shockwave C2 Coronary.